Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
Long Island Bioscience Hub Announces Latest Funded Projects
June 6, 2017
Innovative phase-0 proof-of-concept center continues advancement of commercially promising biomedical innovations.
The Center for Biotechnology at Stony Brook University, on behalf of the Long Island Bioscience Hub (LIBH), announced the recipients of the fourth round of funded projects under the Hub’s technology development and commercialization initiative. Funding for five projects totaling $400,000 has been awarded to applicants from the Hub’s partner institutions. Partner institutions include Stony Brook University, Cold Spring Harbor Laboratory, Brookhaven National Laboratory, and the Feinstein Institute for Medical Research at Northwell Health. Over the last two years, more than $2.5M has been awarded to further the development of commercially promising technologies.
There are two categories of awards under the LIBH funding initiative – Feasibility and Proof-of-Concept. “Feasibility awards” are funded at up to $50,000 and designed to rapidly test the feasibility of new ideas in a “fail-fast-or-proceed” format, or to add value to existing intellectual property leading to new market applications. Proof-of-Concept awards provide up to $100,000 for targeted, milestone driven support for further development, testing, and analysis of existing intellectual property.
In this cycle, two feasibility awards have been given to Stony Brook University researchers exploring technologies that include a novel anti-fungal for life threatening blood infections and a new computational method for macrocyclic drug discovery. Proof-of-Concept projects this cycle include a drug-sensitive and drug-resistant TB combination therapy, a novel therapeutic for the treatment of colorectal cancer, and a next-generation medical imaging tool with applications in mammography.
“While the Long Island Bioscience Hub is only two‐years in existence, it has already had major impacts including the establishment of four companies.” said Clinton T. Rubin, Ph.D., Distinguished Professor, Chair, Department of Biomedical Engineering, and Director, Center for Biotechnology. “Additionally, this round of funding further enhances the LIBH-REACH pipeline that already has resulted in eight patent applications, five options/licenses and more than forty SBIR/STTR applications related to REACH technologies and small business clients.”
“I applaud the efforts of the Long Island Bioscience Hub as they continue to draw out the cutting edge biomedical innovations that exist within our research labs and their work with faculty innovators and the local bioscience community to accelerate commercial development.” said Dr. Richard Reeder, Vice President for Research at Stony Brook University. “Stony Brook University is deeply committed to the translation of basic research and the Hub’s successes demonstrate that we need to continue to foster the activities of the Hub.”
The technology development awards made available by the LIBH are specifically aimed at growing a pipeline of commercially promising biomedical technologies that can be out-licensed for further development or serve as the foundation for new company formations in the region. The main goal of the LIBH is to foster the development of therapeutics, preventatives, diagnostics, devices and research tools emerging from LIBH partner institutions that address diseases within the NIH’s mission.
Funded Projects –May 2017 Awards
“A Small Molecule Drug for the Treatment of Systemic Candidiasis” Nicolas Carpino, PhD and Jarrod French, Stony Brook University – Feasibility Award
“BRIKARD, a Program for Macrocyclic Drug Discovery” Evangelos Coutsias, PhD, Stony Brook University – Feasibility Award
“Selenium multi-Well Avalanche Detectors for Medical Imaging Applications” Amirhossein Goldan, PhD, Stony Brook University – Proof of Concept Award
“Developing Novel miR-129 Mimic Based Therapeutics for Colorectal Cancer” Jingfang Ju, PhD, Stony Brook University – Proof of Concept Award
“Azasteroid for Combination anti-TB Therapy” Nicole Sampson, PhD, Stony Brook University – Proof of Concept Award
The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.
The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.
“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”
Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”
The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.
“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.
As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.
Join as AdvaMed presents “Advancing Public Health with Wearables: Strategic Development of IoMT Biosensing Lifestyle Devices” with MIDI Medical Device Development Corp. and Valencell, Inc. This webinar is presented by Christopher Montalbano, CEO, MIDI Medical Device Development Corp., and Ryan Kraudel, Vice President, Marketing, Valencell, Inc., this webinar will examine the way in which wearables advance public health when a strategic device development approach is utilized to integrate and harmonize: Lifestyle, IoMT, Biosensing, and Physiological Sensing.
In this AdvaMed Event, MIDI & Valencell will cover: • Understand how wearable IoMT devices utilizing Bio-Sensors and Physiological Sensors translate into enhanced healthcare and wellness lifestyles. • Learn how to optimize the selection of sensor (or sensor cluster) through a proven 4-Step approach of: User Experience Monitoring, Body Assessments, Key Body Metric Capture and Sensor Selection. • Learn the 3-Step Innovation Roadmap™ for optimized wearable device development including: Discovery Research™, MVP R&D and AGILE Commercialization under ISO-13485. • Review of Case Studies that demonstrate implementation of these innovation principles yielding advanced wearable IoMT healthcare sensing devices.
[post_title] => Webinar: Advancing Public Health with Wearables: Strategic Development of IoMT Biosensing Lifestyle Devices - September 15th
[post_excerpt] => On September 15 join as MIDI Medical Device Development Corp. AdvaMed, and Valencell, Inc. present “Advancing Public Health with Wearables: Strategic Development of IoMT Biosensing Lifestyle Devices”
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => webinar-advancing-public-health-with-wearables-strategic-development-of-iomt-biosensing-lifestyle-devices-september-15th
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-20 16:02:48
[post_modified_gmt] => 2021-09-20 16:02:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3814
[menu_order] => 38
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4534
[post_author] => 4
[post_date] => 2024-04-08 13:47:00
[post_date_gmt] => 2024-04-08 17:47:00
[post_content] =>
The Center for Biotechnology has announced the appointment of Dr. Dee Dao as Associate Director for Business Development and Investment. In her new role, Dr. Dao will serve as the primary contact on issues related to research, technology development and commercialization for the Center for Biotechnology. Additionally, Dr. Dao will foster new collaborative relationships in order to bolster sponsored research agreements and strategic alliances.
Prior to joining the CFB, Dr. Dao served as a Venture Associate for the NYU Innovation Venture Fund, where she focused on investment opportunities in life science and healthcare. Prior to NYU, Dr. Dao was at the Ludwig Institute for Cancer Research where she contributed to early oncology therapeutic development planning and oversaw intellectual property (IP) strategy to support the clinical development of the Institute’s therapeutics. Before that, Dr. Dao investigated bacterial virulence and immunity to identify new vaccines against Tuberculosis as a postdoctoral fellow in an HHMI laboratory at Albert Einstein College of Medicine.
Currently, Dr. Dao also serves as a mentor for entrepreneurs participating in the Entrepreneurship Lab, a NYCEDC initiative. Dr. Dao received a Ph.D. in Molecular Genetics/Developmental Biology at Columbia University and a B.S. in Chemistry from University of Pittsburgh. Dr. Dao is also an alumnus of the Center for Biotechnology’s Fundamentals of the Bioscience Program in 2010.
“We are thrilled to have Dee join the Center for Biotechnology to lead our technology and business development efforts on behalf of innovators and emerging companies in New York” Diane Fabel, Director of Operations at the Center for Biotechnology said. She continued “Dee brings deep experience working with and funding innovation to her role at the Center which our clients and community will greatly benefit from.”
“I am very happy to join the team at the Center for Biotechnology. I’ve admired the work the Center for Biotechnology has done when it comes to supporting and accelerating the development of biomedical technology in New York State” Dr. Dao said. “I’m looking forward to helping lead the technology and business development efforts of the Center and increase the impact the organization can have on the wealth of innovations in the region”.
[post_title] => Dr. Dee Dao Appointed Associate Director for Business Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => dr-dee-dao-appointed-associate-director-for-business-development
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-24 12:42:43
[post_modified_gmt] => 2025-02-24 17:42:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4534
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 4046
[post_author] => 4
[post_date] => 2023-03-10 16:52:04
[post_date_gmt] => 2023-03-10 16:52:04
[post_content] =>
The Center for Biotechnology has announced a Call for Proposals for our 2023 Applied Research and Development (ARAD) Program. The ARAD program provides matching funds on a competitive basis to support collaborations between Stony Brook University faculty and NY State corporate partners in all areas of medical biotechnology.
These areas include research technologies, diagnostics, therapeutics and medical devices. The primary interest is in supporting development of technologies that will help companies hit commercially relevant milestones, and that have the potential to positively impact the New York State economy.
2023 Proposal Submission: The deadline for receipt of applications is May 8, 2023, 5pm (updated). No exceptions will be made. Applications are accepted and considered on a competitive basis and are subject to the availability of funds. Approval from the Research Foundation Sponsored Programs is not required prior to submission, but will be required if the project is selected for funding. All applications require a letter-of-support from a senior executive of the company confirming their corporate residency in New York State and financial commitment to match-fund the project. Further details are found within the forms pages. A single PDF version of the proposal and letter of support should be submitted to Center for Biotechnology at center_for_biotechnology@stonybrook.edu.
The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.
The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.
“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”
Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”
The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.
“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.
As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.
